N-甲基-O-苯甲酰羟胺 | 66809-88-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-甲基-O-苯甲酰羟胺
• 英文名称: N-methyl-O-benzoylhydroxylamine
• 英文别名: O-Benzoyl-N-methylhydroxylamine；Methylamino Benzoate
• CAS: 66809-88-9
• 化学式: C₈H₉NO₂
• mdl: MFCD17170122
• 分子量: 151.165
• InChiKey: BBEJNBLSSWFDSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-甲基-O-苯甲酰羟胺 在 9-borabicyclo[3.3.1]nonane dimer 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 反应 24.0h， 生成 8-[2-(N,4-dimethylphenylsulfonamido)ethyl]-1,4-dioxaspiro[4.5]dec-8-en-7-yl benzoate
  参考文献：
  名称：

  涉及从头构建芳香 C 环的加兰他敏的全合成

  摘要：

  四环生物碱加兰他敏在许多国家临床上用于轻度至中度阿尔茨海默病的对症治疗，这一特征加上其新颖的分子结构促使人们广泛关注其合成。本研究报告了一种新的、独特的加兰他敏合成，其中 AB 环亚结构和相关的季碳中心是通过使用钯催化的分子内阿尔德烯反应构建的。该过程的产物参与 Tsuji-Trost 型反应以生成半环二烯，该二烯参与正常电子需求的 Diels-Alder 反应，在最初形成的加合物氧化后生成芳族 C 环目标生物碱。

  DOI：

  10.1002/ejoc.201500365
• 作为产物：
  描述：

  4-硝基苯基安息香酸 、 N-甲基羟胺盐酸盐 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 0.42h， 生成 N-甲基-O-苯甲酰羟胺
  参考文献：
  名称：

  Copper-catalyzed redox deacylation of isomeric N- and O-benzoylhydroxylamines

  摘要：

  N- and O-benzoylhydroxylamines are, in principle, capable of forming five-membered metal chelates structurally similar to those of alpha-amino esters. Because alpha-amino esters are hydrolyzed by many metal ions, the metal-promoted or -catalyzed reactions of N- and O-benzoylhydroxylamines were examined. Two metals that are active with alpha-amino esters-Ni(II) and Zn(II)-show no reaction with either benzohydroxamic acid or O-benzoylhydroxylamine in aqueous solution. Cu(II) accelerates the rate of benzoic acid formation with both compounds by factors of up to 60- and 40-fold, respectively, under the conditions evaluated. Both reactions give benzoic acid as product, but hydroxylamine is not a product in either reaction. We observe that O-benzoylhydroxylamine reacts with Cu(II) with net oxidation and with Cu(I) with net reduction of the nitrogenous product. When a substoichiometric amount of Cu(II) is used, copper serves as a catalyst to effect deacylation with redox disproportionation of the starting material.

  DOI：

  10.1021/jo00049a016

文献信息

• [EN] NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS<br/>[FR] NOUVEAUX INHIBITEURS À PETITES MOLÉCULES DE FACTEURS DE TRANSCRIPTION TEAD
  申请人：MASSACHUSETTS GEN HOSPITAL

  公开号：WO2020190774A1

  公开（公告）日：2020-09-24

  The present disclosure compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the TEAD transcription factor, and are useful in the treatment of diseases related to the activity of TEAD transcription factor including, e.g., cancer and other diseases.

  本公开涉及化合物及其组合物和使用方法。这些化合物抑制TEAD转录因子的活性，并可用于治疗与TEAD转录因子活性相关的疾病，例如癌症和其他疾病。
• [EN] FUSED QUINOLINE DERIVATIVE AND USE THEREOF<br/>[FR] DÉRIVÉ DE QUINOLINE FUSIONNÉE ET UTILISATION DE CELUI-CI
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2005105802A1

  公开（公告）日：2005-11-10

  The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein Rl is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6 is (cyclic group optionally having substituent(s)) -carbonyl, and the like; R7, R8, R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7 and R8, R8 and R9, and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; --- represents unsubstituted (i.e., absence) or a single bond; and --- represents a single bond or a double bond, or a salt thereof, and the like.

  本发明旨在提供一种具有神经激肽2（NK2）受体拮抗作用的喹啉衍生物，并涉及一种由式（I）表示的化合物，其中R1是氢原子等；R2是氢原子，可选地具有取代基的碳氢基团等；R3是未取代的（即缺失），氢原子等；R4和R5相同或不同，每个是氢原子，可选地具有取代基的碳氢基团等；R6是（环状基团，可选地具有取代基）-羰基等；R7、R8、R9和R10相同或不同，每个是氢原子，卤素等；或R7和R8、R8和R9、以及R9和R10可以与相邻的碳原子一起形成环；n是1到5的整数；---表示未取代的（即缺失）或单键；---表示单键或双键，或其盐等。
• Pyrrolidine derivatives
  申请人：——

  公开号：US20020049243A1

  公开（公告）日：2002-04-25

  The present invention relates to pyrrolidine derivatives and dimeric forms and/or pharmaceutically acceptable esters, and/or salts thereof. The compounds are useful as inhibitors of metalloproteases, e.g. zinc proteases, particularly zinc hydrolases, and which are effective in treating disease states are associated with vasoconstriction of increasing occurrences.

  本发明涉及吡咯烷衍生物及其二聚体形式和/或药用可接受的酯和/或盐。这些化合物可用作金属蛋白酶抑制剂，例如锌蛋白酶，特别是锌水解酶，对治疗与血管收缩增加发生相关的疾病状态有效。
• [EN] CHEMOKING RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE CHIMIOKINES
  申请人：ABBOTT LAB

  公开号：WO2013010453A1

  公开（公告）日：2013-01-24

  Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

  本文揭示了化学受体拮抗剂的化学式(I)，其中G1、X1、X2和X3如规范中所定义。还描述了包含这种化合物的组合物；以及使用这种化合物和组合物治疗疾病和疾病的方法。
• NGCYCLOARTANONE DERIVATIVES WITH ANTICANCER ACTIVITY
  申请人：Long Christophe

  公开号：US20120077777A1

  公开（公告）日：2012-03-29

  The present invention relates to a compound of following formula (I): or to a pharmaceutically acceptable salt thereof, as well as to pharmaceutical compositions including same and to the use thereof as a drug, in particular for treating a proliferative disease such as cancer.

  本发明涉及以下式（I）的化合物： 或其药学上可接受的盐，以及包括相同的药物组合物和将其用作药物的用途，特别是用于治疗增殖性疾病如癌症。